Amgen Inc. (AMGN) is a Healthcare stock trading at $337.44 (as of 2026-06-18), with a market capitalization of $182.54B and a trailing P/E of 24.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics for conditions including inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its product portfolio includes therapies such as Enbrel, Neulasta, Prolia, Xgeva, Otezla, and Repatha, which are marketed to healthcare providers including physicians, dialysis centers, hospitals, and pharmacies.